In last trading session, Gossamer Bio, Inc. (NASDAQ:GOSS) saw 1,399,628 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $9.49 trading at $0.17 or 1.77% at ring of the bell on the day assigns it a market valuation of $683.18 Million. That closing price of GOSS’s stock is at a discount of -186.09% from its 52-week high price of $27.15 and is indicating a premium of 20.76% from its 52-week low price of $7.52. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.09 Million shares which gives us an average trading volume of 674.7 Million if we extend that period to 3-months.
For Gossamer Bio, Inc. (GOSS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.7. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.85 in the current quarter.
Gossamer Bio, Inc. (NASDAQ:GOSS) trade information
Upright in the green today for gaining 1.77%, in the last five days GOSS remained trading in the green while hitting it’s week-highest on Monday, Oct 12 when the stock touched $13.65- price level, adding 30.48% to its value on the day. Gossamer Bio, Inc.’s shares saw a change of -39.28% in year-to-date performance and have moved -27.28% in past 5-day. Gossamer Bio, Inc. (NASDAQ:GOSS) showed a performance of -27.06% in past 30-days. Number of shares sold short was 9.86 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $22.5 to the stock, which implies a rise of 137.09% to its current value. Analysts have been projecting $12 as a low price target for the stock while placing it at a high target of $31. It follows that stock’s current price would jump +226.66% in reaching the projected high whereas dropping to the targeted low would mean a loss of 26.45% for stock’s current value.
Gossamer Bio, Inc. (GOSS) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -47.6% while estimates for its earnings growth in next 5 years are of 5.2%
Gossamer Bio, Inc. (NASDAQ:GOSS)’s Major holders
Insiders are in possession of 21.67% of company’s total shares while institution are holding 74.36% percent of that, with stock having share float percentage of 94.93%. Investors also watch the number of corporate investors in a company very closely, which is 149 institutions for Gossamer Bio, Inc. that are currently holding shares of the company. Hillhouse Capital Advisors Ltd. is the top institutional holder at GOSS for having 7.42 Million shares of worth $96.47 Million. And as of June 29, 2020, it was holding 9.79% of the company’s outstanding shares.
The second largest institutional holder is Capital International Investors, which was holding about 5.16 Million shares on June 29, 2020. The number of shares represents firm’s hold over 6.8% of outstanding shares, having a total worth of $67.05 Million.
On the other hand, Smallcap World Fund and American Funds Insurance Ser-Growth/Income Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 3171051 shares of worth $41.22 Million or 4.18% of the total outstanding shares. The later fund manager was in possession of 2.3 Million shares on June 29, 2020, making its stake of worth around $29.89 Million in the company or a holder of 3.03% of company’s stock.